The company's 3D human tissue platform includes proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells, and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company changed its name from Organovo Holdings, Inc. to VivoSim Labs, Inc. in April 2025, reflecting a strategic focus on its core bioprinting mission.
Cyborg Score Rationale
The company is quickly burning through cash, with a concerning current ratio of 0.72 and weak overall financial health score. As of September 30, 2025, VivoSim Labs has a trailing 12-month revenue of $140K, indicating severe revenue challenges for a clinical-stage biotech.
Top Insights
Lead candidate FXR314 is in phase 2/3 clinical trial for inflammatory bowel disease with clinical focus on ulcerative colitis and completed phase 1 clinical trial for liver fibrosis with focus on steatohepatitis
In January 2026, VivoSim expanded Asia-Pacific access to NAMKind human-based toxicology services through a new distributor agreement in Korea and China
Market cap is $7.02M as of October 31, 2025 with 2.61M shares outstanding, indicating severe market skepticism
Company has 13 total employees, suggesting minimal operational scale
Named Competitors
3D Tissue Engineering — Alternative 3D tissue models for drug discovery
Organ-on-a-Chip Platform — Microfluidic human tissue models